Incorporation of Unnatural Amino Acids (UAAs) into Highly Complex Peptide Libraries

我们是Orbit Discovery有限公司，一家快速发展的生物技术公司，与其合作伙伴合作，使用高效的体外筛选技术，快速识别和鉴定一系列慢性病的先进多肽治疗药物。我们希望开发合成生物技术，以筛选具有天然多肽所不具有的特性的潜在药物靶标。这意味着我们将生产对各种疾病有更大应用的多肽。这将使稳定的多肽疗法能够更有效地生产，口服时不太可能降解。这本质上意味着，我们将制造更好的药物，可以口服，提高治疗效果，使治疗更容易管理。该项目将使轨道公司能够克服限制靶标特异性、亲和力和可寻址的结构性限制的限制，并使药物开发更安全、更快。

We are Orbit Discovery Ltd, a rapidly growing biotechnology company that works collaboratively with its partners to rapidly identify and characterise advanced peptide therapeutic drugs for a range of chronic diseases using a highly efficient in vitro screening technique.We want to develop synthetic biology technology for screening of potential drug targets with synthetic peptides possessing characteristics not possible in natural peptides. This means that we will make peptides that have a far greater application for a variety of diseases.This will enable more efficient production of stable peptide therapeutics, less likely to degrade when administered orally. Which essentially means, we will make better medicines, that can be taken orally, improving treatment effectiveness and making treatment more manageable.This project will enable Orbit to overcome limitations of structural constraints that limit target specificity, affinity and addressability and enable safer and faster drug development.